Glioblastoma (GBM) represents a compelling disease for kinase inhibitor therapy because most of these tumors harbor genetic alterations that result in aberrant activation of growth factor signaling pathways. The PI3K/mammalian target of rapamycin (mTOR) pathway is dysregulated in over 50% of human GBM but remains a challenging clinical target. Inhibitors against PI3K/mTOR mediators have limited clinical efficacy as single agents. We investigated potential bypass mechanisms to PI3K/mTOR inhibition using gene expression profiling before and after PI3K inhibitor treatment by Affymetrix microarrays. Mitogen-and stress-activated protein kinase 1 (MSK1) was markedly induced after PI3K/mTOR inhibitor treatment and disruption of MSK1 by specific shRNAs attenuated resistance to PI3K/mTOR inhibitors in glioma initiating cells (GICs). Further investigation showed that MSK1 phosphorylates β-catenin and regulates its nuclear translocation and transcriptional activity. The depletion of β-catenin potentiated PI3K/mTOR inhibitor-induced cytotoxicity and the inhibition of MSK1 synergized with PI3K/mTOR inhibitors to extend survival in an intracranial animal model and decreased phosphorylation of β-catenin at Ser 552 . These observations suggest that MSK1/β-catenin signaling serves as an escape survival signal upon PI3K/mTOR inhibition and provides a strong rationale for the combined use of PI3K/mTOR and MSK1/β-catenin inhibition to induce lethal growth inhibition in human GBM.
Introduction
Glioblastoma multiforme (GBM), an aggressive brain tumor, is resistant to traditional chemotherapy and radiation therapy. Over 50% of GBM have PI3KR1/PI3KCA/PTEN mutations (1) . As PI3K pathway activation and PTEN inactivation are associated with a poor prognostic outcome, the PI3K pathway represents an attractive therapeutic target. The downstream effector mammalian target of rapamycin (mTOR) links growth factor signaling through PI3K to energy and nutrient status, protein translation, autophagy, and tumor cell metabolism (2, 3) . Thus, mTOR is a critical integrator that regulates tumor growth, survival, and potentially, cancer drug resistance.
PI3K/mTOR inhibitors produce a partial response, but complete responses are rare. In preclinical experimental models, about half the responders who benefit from PI3K/mTOR inhibition treatment eventually develop drug resistance after a transient response. Therefore, an understanding of the molecular mechanisms that affect cancer cell sensitivity and resistance to PI3K/mTOR inhibitors is greatly needed. Recently, a number of clinical and preclinical studies indicated that ERK signaling is activated upon PI3K inhibition, and ERK signaling might serve as a compensatory pathway to escape PI3K inhibition (4) (5) (6) .
Mitogen-and stress-activated protein kinase 1 (MSK1), also known as RPS6KA5, is a serine/threonine kinase that belongs to RSK (Ribosomal Protein-S6 Kinase) family and is ubiquitously expressed in various tissues and predominantly expressed in the brain, heart, placenta, and skeletal muscles (7) . MSK1 is activated by extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase pathways in response to growth factor and cellular stress stimuli (7) . Activated MSK1 phosphorylates multiple transcription factors and nuclear proteins, increasing their stability or activity. MSK1 phosphorylates CREB at Ser133 and is linked to the regulation of immediate early genes, including c-Fos, Jun B, c-Jun, and Nurr77 (8, 9) . MSK1 has also been shown to mediate NF-κB-dependent transcription through phosphorylation of p65 on Ser276 (10) . In addition, stress-and mitogen-induced phosphorylation of histone H3 and HMG-14 was found to be completely inhibited in primary embryonic fibroblasts from MSK1/MSK2-knockout animals, suggesting that MSK1 is a prominent kinase involved in the nucleosomal response (11) . MSK1 plays a crucial role in integrating different extracellular signals to functionally regulate cell growth and cell death in response to growth factor and cellular stress stimuli (8, 12, 13) . More importantly, MSK1 is required for Ciras-3 cells to maintain malignant phenotype (8) and for hormone-dependent breast cancer growth. (13) , suggesting that MSK1 plays an important role in tumor progression. However, its function in response to PI3K/mTOR pathway inhibition is unknown.
Wnt/β-catenin signaling is important for glioma tumor cell proliferation and tumor progression. Although β-catenin mutations have not been found in glioma tissues and cell lines (14) , β-catenin mRNA and protein levels are increased in GBM and are correlated with malignancy; therefore, they have been proposed as prognostic markers in GBM (15, 16) . In addition, an increased nuclear fraction of β-catenin and the elevated expression of β-catenin target genes such as cyclin D1 and c-Myc have also been observed in high-grade astrocytomas and GBM (15) (16) (17) . These results suggest that increased β-catenin activity is crucial for glioma progression.
In the current study, we determined the response to PI3K/mTOR inhibition in nude mice and in a panel of glioma-initiating cells (GIC), which retain the relevant molecular features of GBMs and serve as preclinical models for studies of tumor biology and therapeutics. We found that, as a result of selective pressure by PI3K/mTOR inhibition, MSK1 was up-regulated and phosphorylated by ERK signaling. In addition, MSK1 phosphorylated and promoted the transcriptional activity of β-catenin, the activity of which is crucial for glioma progression. The loss of function of MSK1 blocked PI3K/mTOR-inhibition induced phosphorylation of β-catenin and attenuated GICs resistance to PI3K/mTOR inhibition. Thus, our results show that MSK1 and β-catenin signaling acted as compensatory survival signaling pathways to escape from anti-PI3K/mTOR drug therapy and provides a strong rationale to combine PI3K/mTOR and MSK1 or β-catenin inhibition in targeted therapy for malignant glioma.
Materials and Methods

Cell lines and reagents
The GIC lines were established by isolating neurosphere-forming cells from fresh surgical specimens of human GBM tissue between the years of 2005 through 2008, as described previously (18) . Cells were authenticated by testing short tandem repeats (STR) using the Applied Biosystems AmpFISTR Identifier kit (Foster City, CA). The last authentication testing was done in March 2014. This study was approved by the institutional review board of The University of Texas MD Anderson Cancer Center (Houston, Texas). These GBM neurospheres were cultured in DMEM/F12 medium containing B27 supplement (Invitrogen, Carlsbad, CA), basic fibroblast growth factor, and epidermal growth factor (20 ng/ml each). The PI3K/mTOR dual inhibitor BEZ235 was from Selleck (Houston, Texas), DS-7423 was provided by Daiichi Sankyo Co., Ltd.
(Tokyo, Japan), and PD-0325901 was from Selleck (Houston, Texas). For in vitro use, all inhibitors were dissolved in dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO).
50% compared with vehicle-treated controls.
Gene arrays, reverse-phase protein arrays, and bioinformatics
For gene expression arrays, cells were treated with BEZ235, DS7423, or dimethyl sulfoxide for 24 hours; RNA was extracted and hybridized to Affymetrix U133 GeneChips. The array data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE79316. For reverse-phase protein arrays (RPPA), cells were incubated with inhibitors with duplicate treatments for 24 hours. Cell lysates were arrayed on nitrocellulose-coated slides and probed for a panel of 217 antibodies that targeted major important signaling molecules and pathways to establish expression level and activation status.
Western blot analysis
Cells were harvested in lysis buffer, as described previously (18) , and subjected to Western blotting. Anti-MSK1, anti-pMSK1, anti--β-catenin, anti-pS552-β-catenin, anti-ERK, anti-pERK, anti-S6, anti-pS6, anti-AKT and anti-pS473-AKT antibodies were from Cell Signaling (Boston, MA). Anti-β-actin antibody was purchased from Sigma (St. Louis, MO) and used as a loading control.
Plasmids and transfection
Myc-DDK-MSK1 plasmid was purchased from Origene (Rockville, MD) and was used for transient transfection. For stable transfection, MSK1 was subcloned into pMy-puro-IRES retrovirus vector. Flag-β-catenin, TOP-flash, and FOP-flash were gifts from Dr. Zhimin Lu (19) .
Lentivirus pLOC-TurboRFP-β-catenin was from GE Healthcare Dharmacon (Pittsburgh, PA). β-catenin S552A mutant was generated by site-directed mutagenesis using the QuikChange kit (Stratagene, La Jolla, CA). Lentiviral vector pLKO.1-mediated expression of shRNAs for MSK1 and pGIPZ-mediated expression of shRNA of β-catenin were purchased from GE (SCR) were produced in HEK293FT cells with the mixed set of packing plasmids, and the viruses were concentrated and titered as previously described (20) . Cells were infected with lentivirus for 2 days and selected with 1 μg/μl puromycin. 
Luciferase reporter assay
In vitro kinase assay
The kinase reactions were performed by mixing purified His-catenin, with or without purified active MSK1, in kinase assay buffer containing 10 mM Tris-HCl (pH 7. 
Animal studies
All animal studies were conducted in the veterinary facilities of MD Anderson in accordance with institutional rules. To create the intracranial disease model, we engrafted GSC20-SCR and GSC20-MSK1-sh cells (5 x 10 5 ) into the caudate nucleus of nude (nu/nu) 6-to 8-week-old mice using a previously described guide-screw system (21) . Animals were randomly divided into 2 groups of 10 mice each. Starting on day 4 after the tumor cell implantation, mice were treated with 6 mg/kg DS7423 in 200 μL of 0.5% methylcellulose solution, and mice in the control group were given an equal volume of vehicle by oral gavage. The treatment frequency was once a day for 5 days, with 2 days off between treatments, for a total duration of 6 weeks. Mice were monitored daily and euthanized when they became moribund. Their whole brains were extracted, rapidly frozen in liquid nitrogen, and stored at −70°C.
Immunohistochemical staining
Sections (5-μm thick) of formalin-fixed, paraffin-embedded whole brains from animals were stained with anti-ki67 (BD Biosciences), anti-MSK1, anti-p-Ser473-AKT, anti-p-Ser235/236S6-S6, and anti-p-Ser552-β-catenin (Cell Signaling Technology, Boston, MA). The sections were visualized using a diaminobenzidine substrate kit, and the slides were examined under a brightfield microscope.
Statistical analysis
The statistical analysis was performed using Student's t-test. The results are presented as the mean of at least 3 independent experiments. A survival analysis was performed using the logrank analysis module in SPSS software version 10.0 (SPSS, Inc., Armonk, NY). Differences were considered significant at P < 0.05 for all comparisons.
Results
PI3K/mTOR dual inhibitors increased MSK1 expression
To identify molecular targets and signatures that contribute to resistance to PI3K/mTOR inhibitors, we performed gene expression profiling, before and after PI3K/mTOR inhibitor treatment, and analyzed the results by Affymetrix microarrays; the top 10 up-regulated genes were identified ( Figure 1A ). We used two PI3K/mTOR inhibitors, BEZ235 (22) and DS7423 (Supplemental Figure S1 for structure), to exclude the possibility of non-specific drug toxicity.
Both BEZ235 and DS7423 are in clinical trials in patients with advanced solid tumors, and a previous study from our laboratory showed that DS7423 is blood-tumor barrier permeable (23).
We report that MSK1 was significantly up-regulated after BEZ235 and DS7423 treatment in all cell lines tested. Because of the important role of MSK1 in tumor progression, we focused on the potential function of MSK1 as an escape kinase for PI3K/mTOR inhibition. To further confirm the response of MSK1 to PI3K/mTOR inhibition, we treated the cells with 100 nM BEZ235 or DS7423 for 24 hours, washed them for another 24 hours, and repeated 3 cycles ( Figure 1E ). Interestingly, MSK1 expression at both the mRNA level ( Figure 1F ) and protein level ( Figure 1G ) was up-regulated after PI3K/mTOR inhibitor treatment and decreased after the inhibitors had been washed out, suggesting that MSK1 expression is induced by PI3K/mTOR inhibition.
In addition to regulating MSK1 expression, PI3K/mTOR inhibition induced MSK1 phosphorylation (Supplemental Figure S3A ). As MSK1 is reported to be phosphorylated by ERK and p38 under extracellular stimuli, we determined whether ERK or p38 phosphorylated MSK1 in response to PI3K/mTOR inhibition. The RPPA data showed that only ERK, not p38, was activated by PI3K/mTOR inhibitors (Supplemental Figure S3B) . Phosphorylation of MSK1 and ERK was further confirmed by time-course treatment with BEZ235 (Supplemental Figure S3C) .
Suppression of ERK activation by the chemical inhibitor PD-0325901 (24) blocked MSK1
phosphorylation induced by BEZ235 (Supplemental Figure S3D) . These results suggest that ERK phosphorylated MSK1 upon PI3K/mTOR inhibition.
Depletion of MSK1 decreased cell resistance to PI3K/mTOR inhibition
To determine the role of MSK1 in response to PI3K/mTOR inhibition, we knocked down MSK1 expression by shRNAs in GSC20 (Figure 2A 
Overexpression of MSK1 increased cell resistance to PI3K/mTOR inhibition
To confirm the function of MSK1 in PI3K/mTOR response, we used GSC11, which is sensitive to PI3K/mTOR inhibition and with low endogenous expression of MSK1, to establish an MSK1-overexpressing cell line ( Figure 3A) . A cell viability assay showed that, compared with vectorinfected cells, GSC11-MSK1 were more resistant to BEZ235 and DS7423 treatment ( Figure 3B and C). The IC 50 of BEZ235 was increased 8.5-fold as a result of MSK1 overexpression (86 nM for vector cells and 724 nM for MSK1-overexpressed cells); similarly, the IC 50 to DS7423 increased 3-fold as a result of MSK1 overexpression (from 105 nM to 399 nM) ( Figure 3D ).
After BEZ235 and DS7423 treatment, the neurospheres derived from MSK1-overexpressing cells were larger and more numerous than those from vector cells ( Figure 3E (Figure 3I and 3J) . Taken together, these data suggest that MSK1 overexpression confers resistance to PI3K/mTOR inhibition.
MSK1 phosphorylated β-catenin at Ser 552
To explore the molecular mechanism by which MSK1 regulates cell proliferation, we analyzed the gene expression profile of GSC20-SCR and GSC20-MSK1-sh and found a panel of β-catenin signaling-targeted genes including MYC (25), MMP2 (26), MMP7 (27) , WISP1 (28), CYR61 (29) , MET (30) etc. were down-regulated by MSK1 shRNA (Supplemental Figure S5 ). This result suggested that MSK1 regulates β-catenin signaling; therefore, we studied the link between β-catenin and MSK1. First, we determined whether MSK1 interacted with β-catenin by coimmunoprecipitation assay. β-catenin was co-immunoprecipitated with Flag-tagged MSK1 by anti-Flag M2 agarose ( Figure 4A) ; conversely, MSK1 was also co-immunoprecipitated with Flag-tagged β-catenin ( Figure 4B ), suggesting a physical interaction between MSK1 and β-catenin.
Since MSK1 is a serine/threonine kinase, we determined whether it phosphorylates β-catenin. We performed in vitro kinase assays with purified active GST-tagged MSK1 mixed with purified His-β-catenin and analyzed a trypsin digest of β-catenin by mass spectrometry. Ser 
was further confirmed by immunoblotting with a commercial specific antibody against p-ser 552 -β-catenin ( Figure 4D ). These results indicate that MSK1 directly phosphorylated β-catenin at Ser 552 in vitro.
To determine whether MSK1 phosphorylates β-catenin in intact cells, we overexpressed MSK1 in GSC11 and detected endogenous β-catenin by immuno-blotting. MSK1 overexpression greatly increased phospho-ser 552 -β-catenin but had little effect on the total protein level of β-catenin ( Figure 4E ). To confirm this result, we overexpressed MSK1 in another cell line GSC42.
Similarly, overexpression of MSK1 in GSC42 also induced phospho-ser 552 -β-catenin without affecting total β-catenin protein level ( Figure 4F ). Collectively, these results indicate that MSK1
directly phosphorylates β-catenin in vitro and in vivo.
PI3K/mTOR inhibitors induced β-catenin phosphorylation through MSK1
As previously reported, AKT phosphorylates β-catenin at Ser 
MSK1 regulated β-catenin localization and transcriptional activity
Since β-catenin localizes in different cellular compartments to execute differential cellular functions, we determined whether β-catenin phosphorylation by MSK1 affects its subcellular distribution. For that, wild type (wt) β-catenin or S552A mutant β-catenin was transfected with or without MSK1. Co-expression of MKS1 led to a partial translocation of β-catenin from the membrane to the nucleus ( Figure 5A ). S552A mutant β-catenin was primarily localized in the cell membrane and did not enter the nucleus even when co-expressed with MSK1.
As Ser 552 phosphorylation is important for the transcriptional activity of β-catenin (31), we co-transfected TCF/LEF-1 luciferase reporter TOP-FLASH or a control vector, FOP-FLASH, with β-catenin and an increased dose of MSK1. Co-transfection of MSK1 increased β-catenin transcriptional activity in a dose-dependent manner ( Figure 5B ). To investigate the mechanisms underlying MSK1-regulated β-catenin transcriptional activity, we performed a ChIP analysis. As shown in Figure 5C , MSK1 increased β-catenin binding to the c-Myc promoter. The expression of β-catenin target genes, including c-Myc, cyclin D1, CYR61, and MMP 9, were up-regulated by MSK1 overexpression (Figure 5D and E). In contrast, the expression of these genes was down-regulated by MSK1 shRNA ( Figure 5F ).
β-catenin was essential for MSK1-mediated resistance to PI3K/mTOR inhibitors
To determine whether β-catenin confers resistance to PI3K/mTOR inhibitors, we knocked down β-catenin expression by shRNAs in a resistant cell line GSC20 (Supplemental Fig. S6A ). 
MSK1 inhibition synergized with PI3K/mTOR inhibitors to extend survival in an intracranial animal model
We determined whether inhibition of MSK1 potentiated PI3K/mTOR inhibition in a xenograft intracranial tumor model of glioma. Immunodeficient mice were injected with GSC20 that had been stably transfected with MSK1-shRNA (MSK1-sh) or SCR as a control. DS7423 (6 mg/kg) was started 4 days after injection for 6 weeks. 
Discussion
PI3K/mTOR inhibitors are being developed as promising anti-cancer agents (32) . However, the results of pre-clinical studies indicate that patients who benefit from PI3K/mTOR treatment eventually develop drug resistance after a transient response (33, 34) . To understand the mechanisms underlying resistance to the PI3K/mTOR inhibitor, the current study analyzed the gene expression profiles of pre-and post-PI3K/mTOR inhibitor treatments in a panel of GIC.
Here, we identified MSK1-upregulation as an adaptive resistance response to PI3K/mTOR inhibition. MSK1 was one of the top 10 up-regulated PI3K/mTOR inhibitor genes and is an attractive target for combination therapy for several reasons: first, it is a kinase; thus, it is potentially targetable. Second, it regulates diverse cellular processes, including cell proliferation and apoptosis, and is linked to tumorigenesis (8, 13, 35) . Moreover, it is implicated in resistance to several agents, including As 2 O 3 , TGF-β, and paclitaxel (12,36,37). In the present study, using quantitative RT-PCR and Western blot analysis, we demonstrated that MSK1 mRNA and protein were up-regulated after PI3K/mTOR inhibitor treatment. However, regulation of MSK1 expression remains largely unknown. Fujita et al showed that MSK1 was a direct target of MiR-148a in PC3 cells and that overexpression of MiR-148a led to decreased MSK1 expression (37) . However, how PI3K/mTOR inhibition leads to up-regulation of MSK1 expression and whether MiR-148a is involved remain to be further elucidated. Nevertheless, we found that MSK1 was activated by ERK in response to PI3K/mTOR inhibition. This result is consistent with those of previous reports that ERK signaling was activated by PI3K/mTOR inhibition (38, 39) and MSK1 was phosphorylated by ERK in various stimuli (9, 11) . Notably, our RPPA data (Supplementary Figure S3B) showed that EKR signaling was activated upon BEZ235 or DS7423 treatment for 24 hours, but other MAPKs, p38 and JNK, were not or slightly affected. As expected, the mTOR signaling was inhibited as indicated by p70S6K and S6 phosphorylation. However, pS473-AKT was not significantly inhibited by PI3K/mTOR inhibition. Time-course treatment with BEZ235 revealed that pS473-AKT was inhibited at beginning but then reactivated at 24 hours (Supplementary Figure S3C) , which might be due to negative feedback by mTORC1-S6K(40), or reactivation by ERK (41) .
The ectopic expression of MSK1 in cells with low endogenous expression and sensitive GIC potentiated resistance to PI3K/mTOR inhibition, while knockdown of MSK1 in cells with high endogenous expression and resistant GIC attenuated resistance both in vitro and in vivo.
These results suggest that deregulation of MSK1 contributes to PI3K/mTOR resistance.
Interestingly, Violeta Serra et al (42) used an ORF library and identified RSK3/RSK4, 2 other RSK family members that mediate resistance to PI3K pathway inhibition in breast cancer. Here, we report that MSK1 mediated resistance to PI3K/mTOR inhibition in GBM. These findings 
suggest that RSK families play a crucial role in resistance to PI3K/mTOR inhibition in addition to their well-known role in tumorigenesis, although different RSKs may be involved in different cancers.
Our in vitro kinase assay showed that MSK1 can directly phosphorylate β-catenin at Ser 552 . This site was reported to be phosphorylated by several kinases, including AKT. In this study, the results that AKT activity was inhibited upon PI3K/mTOR inhibition while β-catenin was phosphorylated at Ser 552 excluded the possibility that AKT phosphorylates β-catenin. The observation of parallel up-regulation of MSK1 expression and β-catenin phosphorylation suggests that MSK1 mediates PI3K/mTOR inhibitor-induced β-catenin phosphorylation.
Consistently, β-catenin phosphorylation induced by PI3K/mTOR inhibitors was blocked by MSK1 depletion in vitro and in vivo, suggesting that MSK1 is the main kinase that phosphorylates β-catenin under the stress of PI3K/mTOR inhibition. Interestingly, MSK1 and AKT shared the same phosphorylation motif (43, 44) that is present in Ser 552 β-catenin. These results suggest that MSK1 serves as a supplemental kinase to AKT to phosphorylate β-catenin and provides a pathway to escape from PI3K/mTOR inhibition.
Phosphorylation of Ser 552
is important for β-catenin nuclear localization and transcriptional activity (31, 45) . Here, we demonstrated that MSK1 phosphorylated β-catenin at 
MSK1
-mediated resistance to PI3K/mTOR inhibition. The function of β-catenin in PI3K/mTOR resistance was also supported by the results of a previous report that β-catenin confers resistance to PI3K/AKT inhibition in colon cancer (46) . Notably, MSK1 depletion not only down-regulated p-S552-β-catenin but also decreased total β-catenin ( Figure 4H,) while interestingly, induction of p-S552-β-catenin by MSK1 overexpression ( Figure 4E (47) . However, overexpression of S552D mutant β-catenin, a mimic of pS552-β-catenin, showed no difference in half-life compared with wt-β-catenin (19) .
These reports together with our results suggested that phosphorylation at Ser 552 is critical but not sufficient for protein stability.
The BBB is a significant obstacle for delivering small molecules to brain tumor (48) and penetration of molecules across BBB is critical to achieve optimal effects. In current study, the IHC results showed that pAKT and pS6 was significantly decreased after DS7423 treatment.
These results, combining our previous pharmacodynamics study (23) , suggested DS7423 can cross BBB to achieve functional concentration to inhibit PI3K/mTOR signaling. While BEZ235 can also cross the BBB in orthotopic glioblastoma models (49) , the potential in vivo synergy of BEZ235 and MSK1 knockdown or inhibitor was not tested in current study. Future study of identifying MSK1 specific inhibitor and combining the inhibitor with BEZ235 or DS7423 is needed for successful clinical combination therapy.
Collectively, our data support the model shown in Figure by Western blot analysis. G) The indicated cells were treated with 100 nM BEZ235 or 100 nM DS7423 for 24 hours, and the cell lysates were analyzed by Western blot analysis. H) GSC20SCR, GSC20-MSK1-sh6, and GSC-MSK1-sh10 were treated with or without DS7423 for 24 hours, and the cell lysates were analyzed by Western blot analysis. p-β-catenin and total β-catenin expression was quantified by Image J, and p-β-catenin induction by DS treatment was shown at the bottom by the ratio of p-β-catenin/ β-catenin normalized to corresponding untreated samples. The distribution of β-catenin was quantified using Image J and percentage of nuclear β-catenin was shown at the bottom. B) TOP-FLASH or FOP-FLASH with β-catenin and MSK1 were transfected into U87 cells for 24 hours. Luciferase activity was determined and normalized with Renilla activity. C) MSK1 was transfected with or without β-catenin into U87 cells. A ChIP assay was performed with β-catenin antibody, and the c-Myc promoter was detected by PCR. β-catenin-targeted genes were detected by real-time PCR in GSC11 (D) and GSC42 (E) that overexpressed vector and MSK1. F) β-catenin target genes were detected by real-time PCR in GSC20 SCR and GSC20-MSK1-sh. intracranial animal model. A) GSC20-SCR and GSC20-MSK1sh were implanted intracranially in nude mice (n=9 for SCR con, n=8 for SCR DS, n=5 for MSK1-sh con, n=8 for MSK1-sh DS); 4 days later, DS7423 (6 mg/kg) was administered orally 5 times a week for 6 weeks. Mice were killed at morbidity, and survival curves were compared using Kaplan-Meier survival plots. B)
Immunostaining of the brain sections of animals that had been treated for 5 weeks. The tissue sections were incubated with antibodies against Ki-67, p-S6, pAKT, MSK1, and p-S552-β- 
